Jean-Marie Sengelen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jean-Marie Sengelen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aurélien Varnoux
Pôle de Psychiatrie Adulte, Centre Hospitalier Esquirol, 87025 Limoges, France
1 shared publication - Benoit Marin
INSERM, U1094, Tropical Neuroepidemiology, Limoges, France
1 shared publication - Dominique Malauzat
Unité de Recherche et d’Innovation, Centre Hospitalier Esquirol, 87025 Limoges, France
1 shared publication - Murielle Girard
Unité de recherche et de neurostimulation, Centre Hospitalier Esquirol, Limoges, France
1 shared publication - Philippe Nubukpo
Pôle Addictologie, Centre Hospitalier Esquirol, 15 rue du Dr Marcland, 87025 Limoges, France ; Département de Recherche et Développement (DRD), Centre Hospitalier Esquirol, 87025 Limoges, France ; Faculté de Médecine, UMR/INSERM1094, 2 rue du Dr Marcland, 87025 Limoges, France
1 shared publication - Sophie Bonnefond
Pôle de Psychiatrie Adulte, Centre Hospitalier Esquirol, 87025 Limoges, France
1 shared publication
Latest Publications
- Open Access
- 31 August 2016
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 15 (1) , 1-11
A prospective hospital study of alcohol use disorders, comorbid psychiatric conditions and withdrawal prognosis
The objective of this study was to describe the profile and alcoholic status of a population with alcohol use disorders (AUD) requesting help from a psychiatric hospital to stop drinking, as well as their clinical outcome and care consumption over the 2 years following the request. The visits were conducted at baseline (M0) and at 6, 12, 18 and 24 months (M6, M12, M18, M24). Demographic, clinical and psychometric data [Beck Depression Inventory (BDI), AUDIT questionnaire, Global Assessment of Functioning (GAF) scale], and information regarding the use of psychiatric care and therapeutics were collected. The 330 subjects included were mostly male, aged 45.2 ± 10.2 years with an employment rate of 55.4 %, living alone (69.1 %), with a psychiatric comorbidity (60.9 %), especially depressive, and with few somatic complications. Their global functioning was poor (GAF score 49.14 ± 15.6), and less than 10 % were addicted to another substance. The abstinence rate at 24 months was 41.4 %, but only 23 % (20) abstained continuously between M0 and M24, and 66.7 % (58) intermittently. The likelihood of abstinence at M24 was greater for females aged over 60 years. The BDI score decreased significantly between M0 and M24. In all, 56.2 % of the participants were re-hospitalized after weaning, but were not integrated in long-term medical care. Abstinence after alcohol withdrawal fluctuated over time indicating the need for long-term support. The treatment of AUD should not target total, continuous abstinence. Prognostic profiles combining socio-demographic, clinical and biological indicators must be established.
- 31 August 2016
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 15 (1) , 1-11
Open AccessA prospective hospital study of alcohol use disorders, comorbid psychiatric conditions and withdrawal prognosis
The objective of this study was to describe the profile and alcoholic status of a population with alcohol use disorders (AUD) requesting help from a psychiatric hospital to stop drinking, as well as their clinical outcome and care consumption over the 2 years following the request. The visits were conducted at baseline (M0) and at 6, 12, 18 and 24 months (M6, M12, M18, M24). Demographic, clinical and psychometric data [Beck Depression Inventory (BDI), AUDIT questionnaire, Global Assessment of Functioning (GAF) scale], and information regarding the use of psychiatric care and therapeutics were collected. The 330 subjects included were mostly male, aged 45.2 ± 10.2 years with an employment rate of 55.4 %, living alone (69.1 %), with a psychiatric comorbidity (60.9 %), especially depressive, and with few somatic complications. Their global functioning was poor (GAF score 49.14 ± 15.6), and less than 10 % were addicted to another substance. The abstinence rate at 24 months was 41.4 %, but only 23 % (20) abstained continuously between M0 and M24, and 66.7 % (58) intermittently. The likelihood of abstinence at M24 was greater for females aged over 60 years. The BDI score decreased significantly between M0 and M24. In all, 56.2 % of the participants were re-hospitalized after weaning, but were not integrated in long-term medical care. Abstinence after alcohol withdrawal fluctuated over time indicating the need for long-term support. The treatment of AUD should not target total, continuous abstinence. Prognostic profiles combining socio-demographic, clinical and biological indicators must be established.
- 1 November 2014
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 29 (8) , 672
Place des applications médicales pour smartphones dans la psychiatrie de demain
RésuméEn France 45 % des possesseurs de téléphone mobile ont un smartphone. Depuis 2010, ce chiffre est en croissance constante. Il existe bon nombre d’applications médicales pour smartphone qui ont apportées un bénéfice dans la prise en charge de pathologies chroniques comme le diabète. Nous nous sommes donc posé la question de la place que pourraient prendre les applications pour smartphone dans la psychiatrie de demain. À travers l’exemple des troubles de l’humeur nous allons évoquer l’histoire de leur évaluation et montrer comment un smartphone peut être utile à la prévention, et au suivi clinique et thérapeutique des patients. Nous discuterons dans un second temps l’impact potentiel de ces technologies en termes de recherche clinique et des risques associés à l’utilisation des données recueillies.
- 1 November 2014
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 29 (8) , 672
Place des applications médicales pour smartphones dans la psychiatrie de demain
RésuméEn France 45 % des possesseurs de téléphone mobile ont un smartphone. Depuis 2010, ce chiffre est en croissance constante. Il existe bon nombre d’applications médicales pour smartphone qui ont apportées un bénéfice dans la prise en charge de pathologies chroniques comme le diabète. Nous nous sommes donc posé la question de la place que pourraient prendre les applications pour smartphone dans la psychiatrie de demain. À travers l’exemple des troubles de l’humeur nous allons évoquer l’histoire de leur évaluation et montrer comment un smartphone peut être utile à la prévention, et au suivi clinique et thérapeutique des patients. Nous discuterons dans un second temps l’impact potentiel de ces technologies en termes de recherche clinique et des risques associés à l’utilisation des données recueillies.